Passage BIO, Inc. insider trading

Every open-market purchase and sale by Passage BIO, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $206,227 1 trade by 1 insider 3 months later: median +10.9% (+6.1% vs S&P 500) Insider sales, 5 years $113,184 2 trades by 2 insiders 3 months later: median −39.0% (−37.8% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Passage BIO, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Passage BIO, Inc.’s insiders pay?

From March 25, 2020 to June 29, 2026, 12 insiders reported 14 open-market purchases and 15 sales not made under a pre-set plan in Passage BIO, Inc. Twelve months after each purchase was reported, the shares were −59.6% against the S&P 500 on average (median −57.4%), over 6 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 26, 2020 into $1,100 by November 2, 2026, −28.5% a year. It held shares 58% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,489 (+11.5% a year), and held throughout $31,666 (+19.1%).

Copying Passage BIO, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Passage BIO, Inc.'s insiders from March 26, 2020, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 58% of the time.

Passage BIO, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Orbimed Capital Gp VII LLC	10% owner	4	−58.7% (1)	0%	5	—	April 17, 2025
Orbimed Advisors LLC	10% owner	1	—	—	5	—	June 26, 2025
Lynx1 Capital Management LP	10% owner	3	−56.1% (1)	0%	0	—	July 24, 2025
Goldsmith Bruce A	CEO and President	2	−82.5% (1)	0%	0	—	March 23, 2022
Nichols Weston	10% owner	2	−47.5% (1)	0%	0	—	June 29, 2026
Borthwick Kathleen	CFO	0	—	—	1	—	January 12, 2026
Cale Edgar B.	GC & Corporate Secretary	0	—	—	1	—	January 3, 2024
Chou William	PRESIDENT AND CEO	0	—	—	1	—	January 12, 2026
Countouriotis Athena	Director	1	−30.3% (1)	0%	0	—	March 25, 2020
Forman Mark S	Chief Medical Officer	0	—	—	1	—	January 3, 2024
King Simona	Chief Financial Officer	0	—	—	1	—	August 1, 2023
Morris Richard Steven	Chief Financial Officer	1	−82.5% (1)	0%	0	—	May 21, 2021

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Passage BIO, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Passage BIO, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −28.2% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
September 30, 2025	2 buying	+29.8%	−1.2%	−63.6%
May 28, 2021	2 buying	−17.7%	−55.1%	−86.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Passage BIO, Inc. · Funds · Politicians